| P50 | author | Forest M. White | Q44735315 |
| P2860 | cites work | Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells | Q28277030 |
| | Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents | Q29547450 |
| | Overriding imatinib resistance with a novel ABL kinase inhibitor | Q30014844 |
| | Gamma-phosphate-linked ATP-sepharose for the affinity purification of protein kinases. Rapid purification to homogeneity of skeletal muscle mitogen-activated protein kinase kinase | Q30467839 |
| | Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors | Q34005966 |
| | Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis | Q37591872 |
| | Discovery of novel targets of quinoline drugs in the human purine binding proteome | Q41916662 |
| | Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. | Q46630170 |
| | Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis | Q83323671 |
| P433 | issue | 9 | |
| P304 | page(s) | 994-996 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | Nature Biotechnology | Q1893837 |
| P1476 | title | On the iTRAQ of kinase inhibitors | |
| P478 | volume | 25 | |